Next Article in Journal
Psychosocial Aspects of Cancer Need Integration into the Treatment Trajectory—But How?
Previous Article in Journal
Erratum: Legalizing Euthanasia or Assisted Suicide: The Illusion of Safeguards and Controls
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 3
10.3747/co.19.1150
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Corrigendum: A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada

by
V. Hirsh
1,*,
B. Melosky
2,
G. Goss
3,
D. Morris
4 and
W. Morzycki
5
1
Hematology–Oncology Services, Santa Cabrini Hospital; Oncology Services, Royal Victoria Hospital and Montreal General Hospital; and Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC, Canada
2
BC Cancer Agency and University of British Columbia, Vancouver, BC, Canada
3
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
4
Tom Baker Cancer Centre and University of Calgary, Calgary, AB, Canada
5
Cancer Care Nova Scotia and Dalhousie University, Halifax, NS, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(3), 228; https://doi.org/10.3747/co.19.1150
Submission received: 7 March 2012 / Revised: 3 April 2012 / Accepted: 6 May 2012 / Published: 1 June 2012

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

In the article’s Acknowledgments, the company that Anna Christofides represents should have been listed as New Evidence [...]

Share and Cite

MDPI and ACS Style

Hirsh, V.; Melosky, B.; Goss, G.; Morris, D.; Morzycki, W. Corrigendum: A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Curr. Oncol. 2012, 19, 228. https://doi.org/10.3747/co.19.1150

AMA Style

Hirsh V, Melosky B, Goss G, Morris D, Morzycki W. Corrigendum: A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Current Oncology. 2012; 19(3):228. https://doi.org/10.3747/co.19.1150

Chicago/Turabian Style

Hirsh, V., B. Melosky, G. Goss, D. Morris, and W. Morzycki. 2012. "Corrigendum: A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada" Current Oncology 19, no. 3: 228. https://doi.org/10.3747/co.19.1150

APA Style

Hirsh, V., Melosky, B., Goss, G., Morris, D., & Morzycki, W. (2012). Corrigendum: A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Current Oncology, 19(3), 228. https://doi.org/10.3747/co.19.1150

Article Metrics

Back to TopTop